Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Indivior, Inc. et al v. Dr. Reddy's Laboratories S.A., et al.
Case Number:
1:14-cv-01451
Court:
Nature of Suit:
Judge:
Firms
Companies
- Aquestive Therapeutics Inc.
- Dr. Reddy's Laboratories Ltd.
- Indivior PLC
- LTS Lohmann Therapie-Systeme AG
Sectors & Industries:
-
June 24, 2022
Dr. Reddy's Gets $72M In Generic Suboxone Settlement
Indivior, Aquestive and Dr. Reddy's Laboratories have ended their yearslong litigation battle over generic versions of the opioid addiction treatment Suboxone, with the Indian drugmaker on Friday saying it will receive $72 million by April 2024.
-
September 19, 2019
Suboxone Maker's 'Gross Manipulation' Prompts $3M Fee Bid
Goodwin-backed Dr. Reddy's Laboratories has asked a Delaware federal judge for more than $3 million in attorney fees after beating Indivior's patent infringement suit over the opioid addiction treatment Suboxone, saying the company took a hopeless case to trial and undermined the litigation by filing a similar suit in New Jersey.
-
September 01, 2017
Dr. Reddy's Cleared Of Infringing Suboxone Patents
Indivior PLC said Friday a Delaware federal judge found a product developed by Dr. Reddy's Laboratories does not infringe three of its patents for Suboxone, clearing the way for a generic version of the opiate addiction treatment, which generates 80 percent of Indivior's revenue.